V

Vaxcell Bio Therapeutics
KOSDAQ:323990

Watchlist Manager
Vaxcell Bio Therapeutics
KOSDAQ:323990
Watchlist
Price: 9 680 KRW 1.36% Market Closed
Market Cap: ₩225.2B

Net Margin

-185.1%
Current
Improving
by 14 678.2%
vs 3-y average of -14 863.4%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-185.1%
=
Net Income
₩-12.4B
/
Revenue
₩6.7B

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-185.1%
=
Net Income
₩-12.4B
/
Revenue
₩6.7B

Peer Comparison

Country Company Market Cap Net
Margin
KR
Vaxcell Bio Therapeutics
KOSDAQ:323990
224.3B KRW
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
394.7B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
187.9B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
175B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
120.2B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
80.6B USD
Loading...
AU
CSL Ltd
ASX:CSL
87.1B AUD
Loading...
NL
argenx SE
XBRU:ARGX
43.8B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.5B USD
Loading...

Market Distribution

Lower than 95% of companies in Korea
Percentile
5th
Based on 2 632 companies
5th percentile
-185.1%
Low
-168 471.3% — -2.9%
Typical Range
-2.9% — 5.8%
High
5.8% — 21 012.5%
Distribution Statistics
Korea
Min -168 471.3%
30th Percentile -2.9%
Median 1.9%
70th Percentile 5.8%
Max 21 012.5%

Vaxcell Bio Therapeutics
Glance View

Market Cap
225.2B KRW
Industry
Biotechnology

Vaxcell-Bio Therapeutics develops anti-cancer therapeutics. The company is headquartered in Hwasun, Jeollanam-Do and currently employs 47 full-time employees. The company went IPO on 2020-09-22. The firm's pipeline consists of the Vax-NK natural killer cell anti-cancer immunotherapy platforms, the Vax-DC dendritic cell anti-cancer immunotherapy platforms, and the Vax-CAR series next-generation advanced anti-cancer immunotherapy platforms. In addition, the Company manufactures and sells cytokine-based boxleukin-15, an anticancer immunotherapy exclusively for dogs. The firm sells its products in domestic and overseas markets.

Vaxcell Bio Therapeutics Intrinsic Value
HIDDEN
Show
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-185.1%
=
Net Income
₩-12.4B
/
Revenue
₩6.7B
What is Vaxcell Bio Therapeutics's current Net Margin?

The current Net Margin for Vaxcell Bio Therapeutics is -185.1%, which is above its 3-year median of -14 863.4%.

How has Net Margin changed over time?

Over the last 2 years, Vaxcell Bio Therapeutics’s Net Margin has increased from -74 867.6% to -185.1%. During this period, it reached a low of -74 867.6% on Dec 31, 2023 and a high of -185.1% on Oct 30, 2025.

Back to Top